Australian Prescriber

Collaborative, interprofessional (partnered) medication charting and prescribing models have been shown to reduce the risk of medication errors at hospital admission and discharge, and reduce patients’ length of stay in hospital.

Diagnosis and management of obstructive sleep apnoea is important. Untreated sleep apnoea results in non-restorative sleep and daytime sleepiness, and may lead to adverse long-term cardiovascular and neurocognitive outcomes.

The updated Australian cardiovascular disease risk guideline and its new calculator, designed with more individual nuance and reclassification factors, enables clinicians to provide highly specific risk estimates and individualised preventive strategies.

The latest monovalent COVID-19 mRNA vaccines, andusomeran and raxtozinameran, are designed to protect against COVID-19 disease caused by Omicron XBB.1.5 and related emerging subvariants.

Faricimab inhibits pathological angiogenesis and restores vascular stability in the eye, improving visual outcomes for patients with neovascular age-related macular degeneration and diabetic macular oedema.

Relugolix is a gonadotropin-releasing hormone antagonist that induces a menopause-like state, reducing severe fibroid-related menstrual symptoms. In combination with estradiol and norethisterone, menopausal symptoms, bone-density loss and endometrial hyperplasia are limited.